Brian A Gordon

List of Publications by Year
in descending order

193 papers	7,887 citations	81900 39 h-index	56724 83 g-index
204 all docs	204 docs citations	204 times ranked	9147 citing authors

#	Article	IF	Citations
1	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nature Medicine, 2019, 25, 277-283.	30.7	610
2	Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Science Translational Medicine, 2016, 8, 338ra66.	12.4	560
3	High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology, 2019, 93, e1647-e1659.	1.1	514
4	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
5	Tau Kinetics in Neurons and the Human Central Nervous System. Neuron, 2018, 97, 1284-1298.e7.	8.1	381
6	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
7	Span, CRUNCH, and Beyond: Working Memory Capacity and the Aging Brain. Journal of Cognitive Neuroscience, 2010, 22, 655-669.	2.3	342
8	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurology, 2019, 76, 264.	9.0	227
9	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
10	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
11	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's and Dementia, 2018, 14, 1460-1469.	0.8	192
12	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology, 2018, 91, e859-e866.	1.1	190
13	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
14	Neurovascular coupling in normal aging: A combined optical, ERP and fMRI study. NeuroImage, 2014, 85, 592-607.	4.2	178
15	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	7.6	150
16	Neuroanatomical correlates of aging, cardiopulmonary fitness level, and education. Psychophysiology, 2008, 45, 825-838.	2.4	140
17	Effects of measurement method, wavelength, and source-detector distance on the fast optical signal. NeuroImage, 2006, 32, 1576-1590.	4.2	125
18	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain, 2019, 142, 1063-1076.	7.6	122

#	Article	IF	Citations
19	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. NeuroImage, 2017, 161, 171-178.	4.2	116
20	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE Îµ4 genotype. Brain, 2018, 141, 1828-1839.	7.6	99
21	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurology, The, 2020, 19, 513-521.	10.2	97
22	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	2.4	84
23	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 2016, 80, 379-387.	5.3	82
24	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	3.1	80
25	Structural correlates of prospective memory. Neuropsychologia, 2011, 49, 3795-3800.	1.6	79
26	Longitudinal Î²-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Nonâ€"Alzheimer Disease Pathophysiology. JAMA Neurology, 2016, 73, 1192.	9.0	77
27	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416.	2.7	76
28	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 67, 95-98.	3.1	73
29	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	10.2	72
30	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology, 2018, 91, e313-e318.	1.1	68
31	Segregation of functional networks is associated with cognitive resilience in Alzheimerâ€™s disease. Brain, 2021, 144, 2176-2185.	7.6	66
32	Effect of Race on Prediction of Brain Amyloidosis by Plasma AÎ²42/AÎ²40, Phosphorylated Tau, and Neurofilament Light. Neurology, 2022, 99, .	1.1	63
33	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
34	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. Alzheimer Disease and Associated Disorders, 2017, 31, 87-93.	1.3	52
35	Prefrontal gray matter volume mediates age effects on memory strategies. NeuroImage, 2014, 90, 326-334.	4.2	50
36	Crossâ€sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid Î² positron emission tomography pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 245-252.	2.4	49

#	Article	IF	Citations
37	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease–informed machine–learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.8	47
38	Neurofilaments in disease: what do we know?. Current Opinion in Neurobiology, 2020, 61, 105-115.	4.2	44
39	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. NeuroImage: Clinical, 2015, 8, 246-252.	2.7	43
40	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. Nature Communications, 2021, 12, 5346.	12.8	43
41	Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 72, 177-185.	3.1	42
42	Socioeconomic Status Mediates Racial Differences Seen Using the <scp>AT(N)</scp> Framework. Annals of Neurology, 2021, 89, 254-265.	5.3	42
43	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101767.	2.7	41
44	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. Neurobiology of Aging, 2015, 36, 1771-1779.	3.1	36
45	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiology of Aging, 2019, 75, 42-50.	3.1	36
46	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834.	1.1	35
47	A diffusion model analysis of episodic recognition in preclinical individuals with a family history for Alzheimer's disease: The adult children study.. Neuropsychology, 2016, 30, 225-238.	1.3	34
48	Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	10.2	34
49	Effects of Aging and Alzheimer's Disease Along the Longitudinal Axis of the Hippocampus. Journal of Alzheimer's Disease, 2013, 37, 41-50.	2.6	32
50	Predicting dysfunctional age-related task activations from resting-state network alterations. NeuroImage, 2020, 221, 117167.	4.2	32
51	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	4.4	31
52	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. Biological Psychiatry, 2021, 89, 776-785.	1.3	30
53	Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT). Alzheimer Disease and Associated Disorders, 2021, 35, 164-168.	1.3	30
54	Comparing Aging and Fitness Effects on Brain Anatomy. Frontiers in Human Neuroscience, 2016, 10, 286.	2.0	29

#	Article	IF	Citations
55	Discovery and validation of autosomal dominant Alzheimer's disease mutations. Alzheimer's Research and Therapy, 2018, 10, 67.	6.2	29
56	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.1	27
57	In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2018, 90, e896-e906.	1.1	27
58	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. NeuroImage, 2022, 256, 119228.	4.2	27
59	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. NeuroImage: Clinical, 2020, 26, 102248.	2.7	24
60	Higher Body Mass Index Is Associated with Lower Cortical Amyloid-β Burden in Cognitively Normal Individuals in Late-Life. Journal of Alzheimer's Disease, 2019, 69, 817-827.	2.6	23
61	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	5.9	23
62	Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. Neurobiology of Aging, 2017, 49, 216.e7-216.e13.	3.1	22
63	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. Cerebral Cortex, 2020, 30, 5686-5701.	2.9	22
64	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 825-837.	1.3	22
65	Frequency analysis of the visual steady-state response measured with the fast optical signal in younger and older adults. Biological Psychology, 2010, 85, 79-89.	2.2	21
66	Association between personality and tau-PET binding in cognitively normal older adults. Brain Imaging and Behavior, 2020, 14, 2122-2131.	2.1	21
67	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of Disease, 2022, 166, 105662.	4.4	21
68	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 96, 233-245.	3.1	20
69	Autosomal dominant and sporadic late onset Alzheimer's disease share a common *in vivo* pathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
70	Evidence for a detrimental relationship between hypertension history, prospective memory, and prefrontal cortex white matter in cognitively normal older adults. Cognitive, Affective and Behavioral Neuroscience, 2013, 13, 405-416.	2.0	18
71	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	1.7	18
72	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17

#	Article	IF	Citations
73	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. Neurology, 2021, 97, e76-e87.	1.1	17
74	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
75	Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
76	Association of *BDNF* Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	9.0	15
77	Spread of activation and deactivation in the brain: does age matter?. Frontiers in Aging Neuroscience, 2014, 6, 288.	3.4	14
78	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	2.4	14
79	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 1119-1129.	2.6	14
80	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. Neurobiology of Aging, 2020, 96, 165-175.	3.1	13
81	Modeling autosomal dominant Alzheimer's disease with machine learning. Alzheimer's and Dementia, 2021, 17, 1005-1016.	0.8	12
82	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 61, 509-513.	2.6	11
83	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Communications, 2020, 2, fcaa102.	3.3	11
84	Ante‐and postmortem tau in autosomal dominant and late‐onset Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 2475-2480.	3.7	10
85	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. Journal of Cognitive Neuroscience, 2021, 33, 279-302.	2.3	10
86	Left caudal middle frontal gray matter volume mediates the effect of age on self-initiated elaborative encoding strategies. Neuropsychologia, 2017, 106, 341-349.	1.6	9
87	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 669-676.	3.7	9
88	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	3.1	9
89	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. Psychological Science, 2021, 32, 849-860.	3.3	8
90	Cerebrospinal fluid Aβ42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability. Neurobiology of Aging, 2021, 98, 116-123.	3.1	7

#	Article	IF	Citations
91	Flortaucipir (tau) PET in LGI1 antibody encephalitis. Annals of Clinical and Translational Neurology, 2021, 8, 491-497.	3.7	7
92	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	4.4	7
93	Regional variability in Alzheimer's disease biomarkers. Future Neurology, 2014, 9, 131-134.	0.5	6
94	Mass spectrometry measures of plasma AÎ², tau and Pâ€‑tau isoformsâ€™ relationship to amyloid PET, tau PET, and clinical stage of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037518.	0.8	6
95	Overview of dominantly inherited AD and topâ€‑line DIANâ€‑TU results of solanezumab and gantenerumab. Alzheimer's and Dementia, 2020, 16, e041129.	0.8	4
96	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	2.4	4
97	Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer's disease. Brain Communications, 2022, 4, .	3.3	4
98	P4â€‑108: RESTINGâ€‑STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1480.	0.8	3
99	Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. European Journal of Neurology, 2019, 26, 1235-1239.	3.3	3
100	Solanezumab inâ€‑depth outcomes. Alzheimer's and Dementia, 2020, 16, e038028.	0.8	3
101	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. Alzheimer's Research and Therapy, 2021, 13, 153.	6.2	3
102	he Effects of Aging and Physical Fitness on Working Memory Capacity. Korean Journal of Cognitive and Biological Psychology, 2012, 24, 107-126.	0.0	3
103	Beta-Amyloid Moderates the Relationship Between Cortical Thickness and Attentional Control in Middle- and Older-Aged Adults. Neurobiology of Aging, 2022, 112, 181-190.	3.1	3
104	Sharper in the morning: Cognitive sundowning revealed with highâ€‑frequency smartphone testing. Alzheimer's and Dementia, 2021, 17, .	0.8	3
105	Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals. Brain, 2019, 142, 2903-2904.	7.6	2
106	Author response: In vivo [18 F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2019, 92, 150-150.	1.1	2
107	Gantenerumab inâ€‑depth outcomes. Alzheimer's and Dementia, 2020, 16, e038049.	0.8	2
108	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. Journal of Neuroimmunology, 2021, 352, 577474.	2.3	2

#	Article	IF	Citations
109	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
110	Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram Syndrome. Frontiers in Neuroscience, 2022, 16, 795317.	2.8	2
111	IC-P-164: Patterns of tau binding in T807-PET imaging. , 2015, 11, P110-P110.		1
112	Measures of metabolism provide insights into hippocampal sclerosis. Brain, 2018, 141, 946-948.	7.6	1
113	ICâ€Pâ€204: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P167.	0.8	1
114	P3â€251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2018, 14, P1170.	0.8	1
115	Socioeconomic status mediating sex and racial differences using the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e041229.	0.8	1
116	Brain network dysfunction associated with blood neurofilament light chain in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e041586.	0.8	1
117	Headâ€toâ€head comparison of [^{18}F]MKâ€6240 and [^{18}F]flortaucipir (AVâ€1451) in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e044688.	0.8	1
118	Default mode network dedifferentiation predicts cognitive performance in Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e044790.	0.8	1
119	A comparison of the Montreal Cognitive Assessment and standard cognitive measures in the National Alzheimerâ€™s Coordinating Center and Knight Alzheimerâ€™s Disease Research Center cohorts. Alzheimer's and Dementia, 2020, 16, e046780.	0.8	1
120	Time course of activation of human occipital cortex measured with the event-related optical signal (EROS). , 2006, , .		1
121	Ageâ€related atrophy persists after screening for preclinical Alzheimer disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
122	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
123	O1-01-01: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers. , 2015, 11, P122-P123.		0
124	P3-175: The ilp: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant. , 2015, 11, P697-P697.		0
125	IC-P-020: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers. , 2015, 11, P24-P25.		0
126	P2-154: Patterns of tau binding in T807-PET imaging. , 2015, 11, P546-P546.		0

#	Article	IF	Citations
127	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
128	ICâ€Pâ€117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimer's and Dementia, 2016, 12, P87.	0.8	0
129	P1â€254: Principal Component Analysis of [18F]â€Avâ€1451 TAU Pet in Alzheimerâ€™S Disease and Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P507.	0.8	0
130	ICâ€Pâ€098: Functional Connectivity with Anterior Temporal Lobe Regions Ordered According to The Braak Progression Scheme Reveals Sequential Coupling to Default Mode and Then Sensory Networks. Alzheimer's and Dementia, 2016, 12, P75.	0.8	0
131	P3â€234: Similarities and Differences in Patterns of [F18]â€AVâ€1451 and [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P915.	0.8	0
132	P3â€283: Functional Connectivity with Anterior Temporal Lobe Regions Ordered According to the Braak Progression Scheme Reveals Sequential Coupling to Default Mode and Then Sensory Networks. Alzheimer's and Dementia, 2016, 12, P946.	0.8	0
133	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2016, 12, P145-P146.		0
134	ICâ€Pâ€206: Similarities and Differences in Patterns of [F18]â€Avâ€1451 And [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P147.	0.8	0
135	O2â€08â€05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0
136	ICâ€Pâ€179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB$_{42}$, and Cognition in Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P130.	0.8	0
137	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
138	[P2â€"372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
139	[P1â€"008]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P233.	0.8	0
140	[P2â€"374]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER'S DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER'S DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P769.	0.8	0
141	[P4â€"244]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN ADâ€DEFINED REGIONS. Alzheimer's and Dementia, 2017, 13, P1370.	0.8	0
142	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.8	0
143	[ICâ€Pâ€061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P50.	0.8	0
144	[ICâ€Pâ€064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P53.	0.8	0

#	ARTICLE	IF	CITATIONS
145	[ICâ€Pâ€138]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P105.	0.8	0
146	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
147	[ICâ€Pâ€180]: FLORTAUCIPIR TAUâ€PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDTâ€JAKOB DISEASE. Alzheimer's and Dementia, 2017, 13, P134.	0.8	0
148	[ICâ€Pâ€196]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER's DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER's DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P144.	0.8	0
149	[ICâ€Pâ€205]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€AVâ€1451 PET. Alzheimer's and Dementia, 2017, 13, P149.	0.8	0
150	[ICâ€01â€"02]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN ADâ€DEFINED REGIONS. Alzheimer's and Dementia, 2017, 13, P1.	0.8	0
151	[ICâ€02â€"02]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P4.	0.8	0
152	[P1â€"351]: THE ASSOCIATION BETWEEN PERSONALITY AND TAU PET DEPOSITION IN COGNITIVELY NORMAL OLDER ADULTS: FINDINGS FROM THE KNIGHT ALZHEIMER DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P391.	0.8	0
153	[P1â€"402]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P427.	0.8	0
154	[P1â€"422]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P440.	0.8	0
155	[P2â€"345]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P754.	0.8	0
156	[O1â€"02â€"01]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P184.	0.8	0
157	[O1â€"02â€"03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
158	[O2â€"05â€"03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND <i>IN VIVO</i> AMYLOID IMAGING. Alzheimer's and Dementia, 2017, 13, P561.	0.8	0
159	[O3â€"09â€"05]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€AVâ€1451 PET. Alzheimer's and Dementia, 2017, 13, P922.	0.8	0
160	[ICâ€Pâ€197]: THE ASSOCIATION BETWEEN PERSONALITY AND TAU PET DEPOSITION IN COGNITIVELY NORMAL OLDER ADULTS: FINDINGS FROM THE KNIGHT ALZHEIMER DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P145.	0.8	0
161	[O1â€"02â€"04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
162	Alzheimer disease biomarkers and synucleinopathy. Neurology, 2018, 90, 537-538.	1.1	0

#	Article	IF	Citations
163	Brian Andrew Gordon. Lancet Neurology, The, 2018, 17, 210.	10.2	0
164	O3â€13â€03: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P1056.	0.8	0
165	ICâ€Pâ€167: ALTERED RESTINGâ€STATE FUNCTIONAL MRI SIGNAL ENTROPY IN TEMPORAL AND PARIETAL LOBES IN SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P140.	0.8	0
166	ICâ€Pâ€162: REGIONAL CORTICAL THINNING PATTERNS IN COGNITIVELY IMPAIRED AND CONVERTER INDIVIDUALS USING OASISâ€3 DATA. Alzheimer's and Dementia, 2018, 14, P136.	0.8	0
167	ICâ€Pâ€207: EXAMINING THE ABILITY OF A TAU SPATIAL SPREAD METRIC TO INDICATE DISEASE PROGRESSION COMPARED TO AN INTENSITYâ€BASED APPROACH. Alzheimer's and Dementia, 2018, 14, P170.	0.8	0
168	ICâ€Pâ€009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P19.	0.8	0
169	ICâ€02â€01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P1.	0.8	0
170	ICâ€Pâ€042: RESTINGâ€STATE FUNCTIONAL CONNECTIVITY ASSOCIATES WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P42.	0.8	0
171	P2â€362: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P829.	0.8	0
172	ICâ€Pâ€043: FUNCTIONAL ARCHITECTURAL DIFFERENCES BETWEEN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND LATE ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P43.	0.8	0
173	ICâ€04â€02: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETAâ€AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P7.	0.8	0
174	ICâ€Pâ€166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS. Alzheimer's and Dementia, 2019, 15, P131.	0.8	0
175	ICâ€Pâ€131: PIB BINDING TOPOGRAPHY BEST CORRELATES WITH YOUNG ADULT GLYCOLYSIS. Alzheimer's and Dementia, 2019, 15, P108.	0.8	0
176	ICâ€Pâ€094: CROSSâ€SECTIONAL AND LONGITUDINAL ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P82.	0.8	0
177	ICâ€Pâ€098: PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P85.	0.8	0
178	O3â€12â€01: ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P914.	0.8	0
179	Association between cerebrospinal fluid neurofilament light chain and markers of neurofibrillary pathophysiology: Findings from the Knight Alzheimer Disease Research Center. Alzheimer's and Dementia, 2020, 16, e037136.	0.8	0
180	Global system segregation enhances reserve in normal aging and Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037930.	0.8	0

#	Article	IF	Citations
181	Tau kinetics in Alzheimer disease and primary tauopathies. Alzheimer's and Dementia, 2020, 16, e039109.	0.8	0
182	Tauopathy in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e041683.	0.8	0
183	APOE4 status influences the amyloid and tau relationship. Alzheimer's and Dementia, 2020, 16, e042093.	0.8	0
184	Socioeconomic status mediates racial differences seen using the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e043216.	0.8	0
185	Crossâ€modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e045905.	0.8	0
186	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomalâ€dominant Alzheimer disease depend on imaging modality. Alzheimer's and Dementia, 2020, 16, e045942.	0.8	0
187	Evaluation of 18 Fâ€MKâ€6240 and 18 Fâ€AVâ€1451 tau PET tracers in Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e046124.	0.8	0
188	Neurofilament light is a nonâ€specific marker of aging and white matter integrity. Alzheimer's and Dementia, 2020, 16, e046169.	0.8	0
189	Vasogenic edema in the frontostriatal tract and the anterior limb of the internal capsule predict cognitive decline in Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e046183.	0.8	0
190	A timeâ€embedding network model captures dynamic longitudinal pathology changes in a dominantly inherited Alzheimer disease population. Alzheimer's and Dementia, 2020, 16, e046335.	0.8	0
191	Investigating whether fractional anisotropy is associated with reduced reaction time cost on an attentional control task. Alzheimer's and Dementia, 2020, 16, e046462.	0.8	0
192	Neuroimaging and Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease. , 2017, , .		0
193	The interaction of <i>APOE</i> genotype and amyloidâ€Î² PET predicts PET but not CSF measures of tauopathy in regions of high <i>APOE</i> mRNA expression. Alzheimer's and Dementia, 2021, 17, .	0.8	0